Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
September 15 2022 - 4:05PM
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the
appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
(CMO).
“Kamal joins Spero with an impressive track
record of building and leading successful anti-infective
franchises,” said Ankit Mahadevia, MD, Chief Executive Officer of
Spero Therapeutics. “This, together with his unique blend of
experience within the biotech industry, at global pharmaceutical
companies, and as an infectious disease physician, make him the
ideal candidate to join Spero as CMO. I am thrilled to have Kamal
on our management team and look forward to working together.”
Dr. Hamed has over 20 years of experience
leading various anti-infective clinical development programs in
antibacterials, antivirals, antimalarials, and antifungals. Before
joining Spero, he was the CMO at Lysovant Sciences, a subsidiary of
Roivant Sciences. Prior to his time at Lysovant, Dr. Hamed was Head
of Clinical Development & Medical Affairs at Basilea
Pharmaceutica. Earlier in his career, he held senior positions in
clinical development and medical affairs at Novartis (including
Therapeutic Area Head for Anti-infectives), Bristol-Myers Squibb,
and Bayer, spearheading the successful global development,
approval, and post-marketing medical affairs support of multiple
anti-infective products.
Prior to joining the pharmaceutical industry,
Dr. Hamed worked as an academic physician for 14 years. He holds an
MD degree from the American University of Beirut, an MPH degree
from Johns Hopkins University, and an MBA degree from the
University of South Florida. Dr. Hamed completed a residency in
Internal Medicine at UMDNJ–Robert Wood Johnson Medical School and a
fellowship in Infectious Diseases at Stanford University School of
Medicine. He is a fellow of both the American College of Physicians
and the Infectious Diseases Society of America and has published
over 110 manuscripts in peer-reviewed journals.
Dr. Hamed commented, “The opportunity to lead
the development of Spero’s pipeline programs is exciting, as each
targets an urgent unmet need in the antibiotic space. If
successful, these programs may provide clear benefits, not only to
patients, but to the entire healthcare system. Spero’s lead
candidate, SPR720, has the potential to be the only novel
first-line oral treatment for nontuberculous mycobacterial
pulmonary disease. SPR206 may be able to provide a new treatment
paradigm for multi-drug resistant Gram-negative infections.
Finally, tebipenem HBr has proven itself to be worthy of ongoing
study and clinical development, given the market size for
complicated urinary tract infection and the unmet patient
need.”
About Spero TherapeuticsSpero
Therapeutics is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing, and
commercializing novel treatments for bacterial infections,
including multi-drug resistant bacterial infections and rare
diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Spero Therapeutics also has an IV-administered next generation
polymyxin product candidate, SPR206, developed from its potentiator
platform, which is in development to treat multi-drug resistant
Gram-negative infections in the hospital setting.
- Tebipenem HBr is an investigational drug in the United States
being developed for the treatment of cUTI, including
pyelonephritis, caused by certain microorganisms, in adult patients
who have limited treatment options; tebipenem HBr is not
FDA-approved.
For more information,
visit https://sperotherapeutics.com.
Forward Looking StatementsThis
press release may contain forward-looking statements. These
statements include, but are not limited to, statements about the
potential regulatory path forward for tebipenem HBr and the
potential approval of tebipenem HBr by the FDA and the timing
thereof; the potential value of tebipenem HBr; the future
development and commercialization of SPR720, SPR206, and tebipenem
HBr; the design, initiation, timing, progress and results of
Spero’s preclinical studies and clinical trials and its research
and development programs; and management’s assessment of the
results of such preclinical studies and clinical trials. In some
cases, forward-looking statements can be identified by terms such
as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,”
“could,” “intent,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of
these terms or other similar expressions. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including whether the FDA
will ultimately approve tebipenem HBr and, if so, the timing of any
such approval; whether the FDA will require any additional clinical
data or place labeling restrictions on the use of tebipenem HBr
that would add costs for Spero, delay approval and/or reduce the
commercial prospects of tebipenem HBr; whether any third parties
would be interested in partnering with Spero to pursue continued
efforts to obtain FDA approval of tebipenem HBr, or acquiring
rights to the tebipenem HBr program from Spero through a
partnership arrangement; the COVID-19 pandemic; Spero’s need for
additional funding; the risk that Spero may not be able to address
the FDA's concerns with respect to tebipenem HBr; the lengthy,
expensive, and uncertain process of clinical drug development for
SPR720 and SPR206; whether results obtained in preclinical studies
and clinical trials will be indicative of results obtained in
future clinical trials; Spero’s reliance on third parties to
manufacture, develop, and commercialize its product candidates, if
approved; the ability to commercialize Spero’s product candidates,
if approved; Spero’s ability to retain key personnel; whether
Spero’s cash resources will be sufficient to fund its continuing
operations for the periods and/or trials anticipated; and other
factors discussed in the “Risk Factors” set forth in filings that
Spero periodically makes with the U.S. Securities and Exchange
Commission. The forward-looking statements included in this press
release represent Spero’s views as of the date of this press
release. Spero anticipates that subsequent events and developments
will cause its views to change. However, while Spero may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Spero’s views as of any date subsequent to the date of
this press release.
Investor Relations Contact: Ted
JenkinsVice President, Investor Relations and Strategic
FinanceTJenkins@sperotherapeutics.com (617) 798-4039
Media Inquiries:
media@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2023 to Apr 2024
